Alirocumab does not impact AF risk after ACS

In patients with ACS, the PCSK9 inhibitor alirocumab did not impact the development of atrial fibrillation compared with placebo, according to new data from the ODYSSEY Outcomes trial.
While history of AF conferred greater risk for major adverse CV events during follow-up, the risk did not vary by assignment to alirocumab (Praluent, Sanofi/Regeneron) or placebo, according to the researchers.
As Healio previously reported, in the main results of ODYSSEY Outcomes, alirocumab was associated with reduced risk for major adverse CV events, defined as CHD death, nonfatal MI, ischemic stroke and

In patients with ACS, the PCSK9 inhibitor alirocumab did not impact the development of atrial fibrillation compared with placebo, according to new data from the ODYSSEY Outcomes trial.
While history of AF conferred greater risk for major adverse CV events during follow-up, the risk did not vary by assignment to alirocumab (Praluent, Sanofi/Regeneron) or placebo, according to the researchers.
As Healio previously reported, in the main results of ODYSSEY Outcomes, alirocumab was associated with reduced risk for major adverse CV events, defined as CHD death, nonfatal MI, ischemic stroke and